Publications by authors named "Sheryl Forbes"

Claim this Profile
C
Consensus Building to Identify Nursing Research Priorities Among Oncology Nurses: A Delphi Study in a National Cancer Institute-Designated Comprehensive Cancer Center.
Eileen Danaher Hacker, Sheryl Forbes, Ashley Martinez, Anecita Fadol, Jessica Vaughn

Cancer Nurs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Empowerment to Achieve Clinical Research Nurse Integration Within Academic Medical Centers: A Comparative Analysis of 3 Models.
Amanda Brock, Tara Bresnahan, Catriona Grant, Doyle Bosque, Kathleen Fitch, Sheryl Forbes

J Nurs Adm· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation and Evaluation of a Clinical Trial Communication Tool for Frontline Clinical Staff.
Doyle Bosque, Joelle Delaney, Sheryl G Forbes, Kelly J Brassil

Clin J Oncol Nurs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconciliation and Disposal of Oral Medication: Creating a Safe Process for Clinical Research Personnel.
Doyle Bosque, Sheryl Forbes, Erica N Ward, Joelle Delaney, G Tobin Meyers

Clin J Oncol Nurs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
Paolo Strati, Preetesh Jain, Ralph J Johnson, Sheryl Forbes, Lei Feng

Blood· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethical Challenges Encountered by Clinical Trials Nurses: A Grounded Theory Study.
Sheryl G Forbes, Carolyn A Phillips

Oncol Nurs Forum· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Mediated Therapies in Lymphoma.
Sheryl G Forbes, Haleigh E Mistry

Semin Oncol Nurs· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide plus rituximab (R ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
Melody R Becnel, Loretta J Nastoupil, Felipe Samaniego, Richard E Davis, M J You, Sheryl G Forbes

Br J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
Haleigh Mistry, Sheryl G Forbes, Nathan Fowler

Clin J Oncol Nurs· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Chan Yoon Cheah, Loretta J Nastoupil, Sattva S Neelapu, Sheryl G Forbes, Yasuhiro Oki

Blood· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis